Tissue proteomics studies in the investigation of prostate cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Liptay MJ, Mascaux C. TNM Staging. In: J-P S, Wa F, Eds. Malignant tumors of the lung. Berlin, Heidelberg: Springer; 2004. p. 183–188.
   Google Scholar
• Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974.
   PubMed Web of Science ®Google Scholar
• NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN FrameworkTM) [Internet]. Available from: https://www.nccn.org/framework/.
   Google Scholar
• Compton CC, Byrd DR, Garcia-Aguilar J, et al., editors. AJCC cancer staging atlas. New York, NY: Springer.
   Google Scholar
• Schröder FH, Hermanek P, Denis L, et al. The TNM classification of prostate cancer. Prostate Suppl. 1992;4:129–138.
   PubMedGoogle Scholar
• Zagars GK, Geara FB, Pollack A, et al. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer. 1994;73(7):1904–1912.
   PubMed Web of Science ®Google Scholar
• Egevad L, Delahunt B, Srigley JR, et al. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading. APMIS. 2016;124(6):433–435.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938–1942.
   PubMed Web of Science ®Google Scholar
• Loberg RD, Logothetis CJ, Keller ET, et al. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol. 2005;23(32):8232–8241.
   PubMed Web of Science ®Google Scholar
• Romero Otero J, Garcia Gomez B, Campos Juanatey F, et al. Prostate cancer biomarkers: an update. Urol Oncol. 2014;32(3):252–260.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet. 2014;384(9959):2027–2035.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–132.
   PubMedGoogle Scholar
• de Koning HJ, Gulati R, Moss SM, et al. The efficacy of prostate-specific antigen screening: impact of key components in the ERSPC and PLCO trials. Cancer. 2018;124(6):1197–1206.
   PubMed Web of Science ®Google Scholar
• Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449–455.
   PubMed Web of Science ®Google Scholar
• Prensner JR, Rubin MA, Wei JT, et al. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127rv3.
   PubMed Web of Science ®Google Scholar
• Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000;163(4):1144–1148. discussion 1148.
   PubMed Web of Science ®Google Scholar
• Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435–448.
   PubMed Web of Science ®Google Scholar
• Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011;117(10):2058–2066.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328.
   PubMed Web of Science ®Google Scholar
• Chen RC, Basak R, Meyer A-M, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141–1150.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–2246.
   PubMed Web of Science ®Google Scholar
• Shoag J, Barbieri CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016;18(4):543–548.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical PracticeGuidelines in oncology: prostate cancer, version 3.2012; [Internet]. cited.10.Jan.2018) Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
   Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–137.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Feng Z, Trock BJ, et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019–1024.
   PubMed Web of Science ®Google Scholar
• You S, Knudsen BS, Erho N, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016;76(17):4948–4958.
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Mo F, Wang K, et al. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol. 2014;15(8):426.
   PubMed Web of Science ®Google Scholar
• Beyene B, Haile G. Review on Proteomics Technologies and Its Application for Crop Improvement. Innovative Syst Des Eng. 2016.
   Google Scholar
• Shi T, Song E, Nie S, et al. Advances in targeted proteomics and applications to biomedical research. Proteomics. 2016;16(15–16):2160–2182.
   PubMed Web of Science ®Google Scholar
• Bauça JM, Martínez-Morillo E, Diamandis EP. Peptidomics of urine and other biofluids for cancer diagnostics. Clin Chem. 2014;60(8):1052–1061.
   PubMed Web of Science ®Google Scholar
• Vandekerkhove G, Chi KN, Wyatt AW. Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 2017.
   PubMedGoogle Scholar
• Ummanni R, Mundt F, Pospisil H, et al. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PLoS ONE. 2011;6(2):e16833.
   PubMed Web of Science ®Google Scholar
• Ummanni R, Barreto F, Venz S, et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res. 2012;11(4):2452–2466.
   PubMed Web of Science ®Google Scholar
• Nicolussi A, D’Inzeo S, Capalbo C, et al. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017;6(2):139–153.
   PubMedGoogle Scholar
• Han Z, Zhang Y, He H, et al. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Med Oncol. 2012;29(4):2877–2888.
   PubMed Web of Science ®Google Scholar
• Jiang F, He H, Zhang Y, et al. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis. PLoS ONE. 2013;8(5):e63941.
   PubMed Web of Science ®Google Scholar
• Pallua JD, Schaefer G, Seifarth C, et al. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. J Proteomics. 2013;91:500–514.
   PubMed Web of Science ®Google Scholar
• Pin E, Stratton S, Belluco C, et al. A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. Mol Oncol. 2016;10(10):1585–1594.
   PubMed Web of Science ®Google Scholar
• Staunton L, Tonry C, Lis R, et al. Pathology-driven comprehensive proteomic profiling of the prostate cancer tumor microenvironment. Mol Cancer Res. 2017;15(3):281–293.
   PubMed Web of Science ®Google Scholar
• Chen H, Xu C, Jin Q, et al. S100 protein family in human cancer. Am J Cancer Res. 2014;4(2):89–115.
   PubMed Web of Science ®Google Scholar
• Wang X, Han J, Hardie DB, et al. The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers. J Mass Spectrom. 2016;51(1):86–95.
   PubMed Web of Science ®Google Scholar
• Ahmad R, Nicora CD, Shukla AK, et al. An efficient method for native protein purification in the selected range from prostate cancer tissue digests. Chin Clin Oncol. 2016;5(6):78.
   PubMed Web of Science ®Google Scholar
• Mi Y, Sun C, Wei B, et al. Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells. Biochem Biophys Res Commun. 2018;495(1):473–480.
   PubMed Web of Science ®Google Scholar
• Iglesias-Gato D, Wikström P, Tyanova S, et al. The proteome of primary prostate cancer. Eur Urol. 2016;69(5):942–952.
   PubMed Web of Science ®Google Scholar
• Marmiroli R, Antunes AA, Reis ST, et al. Standard surgical treatment for benign prostatic hyperplasia is safe for patients over 75 years: analysis of 100 cases from a high-volume urologic center. Clinics. 2012;67(12):1415–1418.
   PubMed Web of Science ®Google Scholar
• Chang RTM, Kirby R, Challacombe BJ. Is there a link between BPH and prostate cancer? . Practitioner. 2012. 2. 256(1750):13–16.
   PubMedGoogle Scholar
• Garbis SD, Tyritzis SI, Roumeliotis T, et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2008;7(8):3146–3158.
   PubMed Web of Science ®Google Scholar
• Ummanni R, Junker H, Zimmermann U, et al. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett. 2008;266(2):171–185.
   PubMed Web of Science ®Google Scholar
• Hu J, He J, Kuang Y, et al. Expression and significance of 90K/Mac-2BP in prostate cancer. Exp Ther Med. 2013;5(1):181–184.
   PubMed Web of Science ®Google Scholar
• Alaiya AA, Oppermann M, Langridge J, et al. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci. 2001;58(2):307–311.
   PubMed Web of Science ®Google Scholar
• Lexander H, Palmberg C, Hellman U, et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics. 2006;6(15):4370–4380.
   PubMed Web of Science ®Google Scholar
• Alaiya AA, Al-Mohanna M, Aslam M, et al. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int J Oncol. 2011;38(4):1047–1057.
   PubMed Web of Science ®Google Scholar
• Lisitskaia KV, Eremina LS, Ivanov AV, et al. [Study of Dj-1 protein in tissue specimens, cultured cells and serum of prostate cancer patients]. Biomed Khim. 2011;57(4):392–401.
   PubMedGoogle Scholar
• Sun C, Song C, Ma Z, et al. Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Sci. 2011;9:22.
   PubMed Web of Science ®Google Scholar
• Davalieva K, Kostovska IM, Kiprijanovska S, et al. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer. Prostate. 2015;75(14):1586–1600.
   PubMed Web of Science ®Google Scholar
• Grubb RL, Deng J, Pinto PA, et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res. 2009;8(6):3044–3054.
   PubMed Web of Science ®Google Scholar
• Khan AP, Poisson LM, Bhat VB, et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics. 2010;9(2):298–312.
   PubMed Web of Science ®Google Scholar
• Skvortsov S, Schäfer G, Stasyk T, et al. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res. 2011;10(1):259–268.
   PubMed Web of Science ®Google Scholar
• Pang J, Liu W-P, Liu X-P, et al. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res. 2010;9(1):216–226.
   PubMed Web of Science ®Google Scholar
• Gao X, Pang J, Li LY, et al. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010;29(32):4555–4566.
   PubMed Web of Science ®Google Scholar
• Yocum AK, Khan AP, Zhao R, et al. Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer. Proteomics. 2010;10(19):3506–3514.
   PubMed Web of Science ®Google Scholar
• Shipitsin M, Small C, Choudhury S, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer. 2014;111(6):1201–1212.
   PubMed Web of Science ®Google Scholar
• Davalieva K, Kiprijanovska S, Polenakovic M. Assessment of the 2-d gel-based proteomics application of clinically archived formalin-fixed paraffin embedded tissues. Protein J. 2014;33(2):135–142.
   PubMed Web of Science ®Google Scholar
• Ostasiewicz P, Zielinska DF, Mann M, et al. Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. J Proteome Res. 2010;9(7):3688–3700.
   PubMed Web of Science ®Google Scholar
• Geisler C, Gaisa NT, Pfister D, et al. Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. Biomed Res Int. 2015;454256:2015.
   Google Scholar
• Tian Y, Bova GS, Zhang H. Quantitative glycoproteomic analysis of optimal cutting temperature-embedded frozen tissues identifying glycoproteins associated with aggressive prostate cancer. Anal Chem. 2011;83(18):7013–7019.
   PubMed Web of Science ®Google Scholar
• Chen J, Xi J, Tian Y, et al. Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody-based assays on tissue specimens. Proteomics. 2013;13(15):2268–2277.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen J, Sethi A, et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics. 2014;13(7):1753–1768.
   PubMed Web of Science ®Google Scholar
• Chen L, Fang B, Giorgianni F, et al. Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis. Electrophoresis. 2011;32(15):1984–1991.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–243.
   PubMed Web of Science ®Google Scholar
• Aryee MJ, Liu W, Engelmann JC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5(169):169ra10.
   PubMed Web of Science ®Google Scholar
• Drake JM, Graham NA, Lee JK, et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013;110(49):E4762–E4769.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. (2015);163(4):1011–1025.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009;101(12):878–887.
   PubMedGoogle Scholar
• Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90(10):766–771.
   PubMed Web of Science ®Google Scholar
• Frantzi M, Latosinska A, Merseburger AS, et al. Recent progress in urinary proteome analysis for prostate cancer diagnosis and management. Expert Rev Mol Diagn. 2015;15(12):1539–1554.
   PubMed Web of Science ®Google Scholar
• Chandran UR, Dhir R, Ma C, et al. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer. 2005;5:45.
   PubMed Web of Science ®Google Scholar
• Rybicki BA, Rundle A, Kryvenko ON, et al. Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer. 2016;138(12):2884–2893.
   PubMed Web of Science ®Google Scholar
• Lee G, Veltri RW, Zhu G, et al. Nuclear shape and architecture in benign fields predict biochemical recurrence in prostate cancer patients following radical prostatectomy: preliminary findings. Eur Urol Focus. 2016.
   Google Scholar
• Mischak H, Vlahou A, Righetti PG, et al. Putting value in biomarker research and reporting. J Proteomics. 2014;96:A1–A3.
   PubMed Web of Science ®Google Scholar
• Landau KS, Na I, Schenck RO, et al. Unfoldomics of prostate cancer: on the abundance and roles of intrinsically disordered proteins in prostate cancer. Asian J Androl. 2016;18(5):662–672.
   PubMed Web of Science ®Google Scholar
• Prassas I, Chrystoja CC, Makawita S, et al. Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Med. 2012;10:39.
   PubMed Web of Science ®Google Scholar
• Shishkin SS, Kovalyov LI, Kovalyova MA, et al. “Prostate cancer proteomics” database. Acta Naturae. 2010;2(4):95–104.
   PubMed Web of Science ®Google Scholar
• Chen C, Shen H, Zhang L-G, et al. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer. Int J Mol Med. 2016;37(6):1576–1586.
   PubMed Web of Science ®Google Scholar
• Zhu B, Song N, Shen R, et al. Integrating clinical and multiple omics data for prognostic assessment across human cancers. Sci Rep. 2017;7(1):16954.
   PubMedGoogle Scholar
• Latonen L, Afyounian E, Jylhä A, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9(1):1176.
   PubMedGoogle Scholar
• Meller S, Meyer H-A, Bethan B, et al. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer. Oncotarget. 2016;7(2):1421–1438.
   PubMedGoogle Scholar
• Yap TA, Smith AD, Ferraldeschi R, et al. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov. 2016;15(10):699–718.
   PubMed Web of Science ®Google Scholar
• Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2(46):46ps42.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
   PubMed Web of Science ®Google Scholar